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Background: The Oncotype DX® Prostate Cancer Assay is a multi-gene RT-PCR expression assay that was developed
for use with fixed paraffin-embedded (FPE) diagnostic prostate needle biopsies containing as little as 1 mm of
prostate tumor in the greatest dimension. The assay measures expression of 12 cancer-related genes representing
four biological pathways and 5 reference genes which are algorithmically combined to calculate the Genomic
Prostate Score (GPS). This biopsy-based assay has been analytically and subsequently clinically validated as a
predictor of aggressive prostate cancer. The aim of this study was to validate the analytical performance of the
Oncotype DX Prostate Cancer Assay using predefined acceptance criteria.
Results: The lowest quartile of RNA yields from prostate needle biopsies (six 5 μm sections) was between 19 and
34 ng. Analytical validation of the process requiring as little as 5 ng of RNA met all pre-defined acceptance criteria.
Amplification efficiencies, analytical sensitivity, and accuracy of gene assays were measured by serially diluting an
RNA sample and analyzing features of the linear regression between RNA expression measured by the crossing
point (Cp) versus the log2 of the RNA input per PCR assay well. Gene assays were shown to accurately measure
expression over a wide range of inputs (from as low as 0.005 ng to 320 ng). Analytical accuracy was excellent with
average biases at qPCR inputs representative of patient samples <9.7% across all assays while amplification
efficiencies were within ±6% of the median. Assessments of reproducibility and precision were performed by
testing 10 prostate cancer RNA samples over multiple instruments, reagent lots, operators, days (precision), and RNA
input levels (reproducibility) using appropriately parameterized linear mixed models. The standard deviations for
analytical precision and reproducibility were 1.86 and 2.11 GPS units (100-unit scale) respectively.
Conclusions: The Oncotype DX Prostate Cancer Assay, a clinical RT-PCR assay specifically designed for use with
prostate needle biopsies, has been analytically validated using very limited RNA inputs. The assay requirements and
analytical performance will provide physicians with test results from a robust and reliable assay which will enable
improved treatment decisions for men diagnosed with early-stage prostate cancer.
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Prostate cancer is one of the most common malignan-
cies in men with an estimated 250,000 new cases being
diagnosed in the US in 2012, mostly as a consequence of
PSA screening [1]. Given that most newly diagnosed
cases represent low-risk disease, with less that 3% of
men dying of prostate cancer, active surveillance rather
than immediate treatment has been broadly endorsed by
practice guidelines to be a valid treatment option for
many men. Nonetheless, a large majority of men with
low-risk, early stage disease still undergo aggressive
intervention with radical prostatectomy and/or radiation
therapy [2], despite their attendant long-term side effects
and cost, in large part because clinicians are uncertain as
to the accuracy of conventional methods for discrimina-
ting low-risk from high-risk disease. A number of risk
assessment tools (e.g. nomograms), based on clinical
and pathologic features such as serum PSA level,
clinical stage and biopsy Gleason Score, are currently
being used for risk stratification of men with early-
stage prostate cancer [3]. Although these tools have
some predictive value, a substantial fraction of men
expected to have low-risk disease are found to have
more aggressive disease at prostatectomy [4]. Clearly
there is a need for more accurate discrimination of
low risk disease from aggressive prostate cancers at
the time of diagnosis.
There is a growing recognition that molecular
biomarkers can complement conventional clinical and
pathologic parameters to personalize the care of cancer
patients. However, incorporation of biomarkers into
standard clinical practice requires a level of validation
which is not often achieved. In order for a biomarker to
enter wide clinical practice it needs to demonstrate evi-
dence of strong analytical validity, clinical validity, and
clinical utility [5]. Indeed, successful clinical validation
may be challenging unless the biomarker is based on a
robust, analytically validated platform. Genomic Health,
Inc. has developed a family of analytically [6,7] and
clinically-validated, multi-gene real-time polymerase
chain reaction (RT-PCR) assays (Oncotype DX® Assays)
which identify underlying biology in an individual pa-
tient’s tumor to help guide treatment decisions in inva-
sive node negative and node positive breast cancer
[8-11], breast ductal carcinoma in situ [12] and stage
II/III colon cancer [13-15]. Since its introduction in
2004, the Oncotype DX Breast Cancer Assay has become
widely used in standard clinical practice, and is incorpo-
rated into the major oncology practice guidelines, in-
cluding NCCN and ASCO [16,17].
In order to impact clinical decision-making at the time
of diagnosis, the Oncotype DX Prostate Cancer Assay
was specifically designed for analysis of fixed, paraffin-
embedded (FPE) prostate needle biopsy tissue. Some ofthe key challenges in developing this biopsy-based assay
for prostate cancer include the heterogeneous and multi-
focal nature of the disease, and the very small amounts
of tumor tissue available from diagnostic prostate needle
biopsies. Most newly diagnosed prostate cancer patients
harbor low-volume disease that may be diagnosed
from a single biopsy core [18]. A series of analytical
studies were performed to optimize sensitivity of the
analytical component of the Oncotype DX Prostate
Cancer Assay platform and enable processing of small
volume tissue from prostate biopsies. Some of the most
notable changes include addition of a multiplexed
preamplification step after reverse transcription and
combining the genomic DNA detection step with the
quantitative PCR step. Considering that the RNA yields
of many samples cannot be reliably measured with
current methods, the sample quality is determined pri-
marily by the expression of reference genes rather than
mass as a measure of the amplifiable RNA. The analyt-
ical portion of the Oncotype DX Prostate Cancer Assay
was designed to target 20 ng as the nominal input,
however the assay accommodates samples with lower
concentration through variable RNA inputs, thus enab-
ling the assay to perform well with RNA inputs which
are 110–180 fold lower than required by the Oncotype
DX Colon and Breast Cancer Assays [6,7]. The Oncotype
DX Prostate Cancer Assay includes 5 reference genes
and 12 cancer genes representing distinct biological
pathways with a known role in prostate tumorigenesis:
the androgen pathway (AZGP1, KLK2, SRD5A2, and
FAM13C), cellular organization (FLNC, GSN, TPM2, and
GSTM2), proliferation (TPX2), and stromal response
(BGN, COL1A1, and SFRP4). Reference gene norma-
lization is used to control for sources of pre-analytical
and analytical variability as well as allow for variable
RNA inputs. Reference normalized expression of the 12
cancer-related genes are used to calculate the Genomic
Prostate Score (GPS), which has been shown to predict
adverse prostate cancer pathology beyond conventional
clinical/pathologic factors in a recently completed
clinical validation study [19].
Prior to initiation of the clinical validation study,
analytical validation studies, with pre-specified end-
points and acceptance criteria, were conducted to
ensure that the analytical component of the Oncotype
DX Prostate Cancer Assay is well-controlled and pro-
duces reliable assessment of RNA from individual
FPE prostate tumor tissue. These studies demon-
strated analytical validity of the gene assays com-
prising the Oncotype DX Prostate Cancer Assay
with respect to analytical sensitivity, bias, amplifica-
tion efficiency, precision and reproducibility, and also
validated the precision and reproducibility of the
resulting GPS.
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Tumor blocks and samples
FPE needle biopsies were provided by the Cleveland Clinic
Pathology and Laboratory Medicine Institute and Glickman
Urological and Kidney Institute (C. M-G., E.A.K., S.M.F.)
and were centrally reviewed by two pathologists (C.M-G
and S.M.F). The use of the samples has been approved by
the Cleveland Clinic Institutional Review Board. All biop-
sies were sectioned into eight 5 μm sections. The top and
the bottom slides were hematoxylin and eosin (H&E)
stained and the presence of tumor was confirmed by a
board-certified pathologist. The tumor area was marked in
the top H&E slide and the markings were transferred to the
subsequent 6 unstained slides. The tumor was manually
dissected from each unstained slide using a scalpel
blade and transferred into a microcentrifuge tube. FPE
prostate cancer samples from radical prostatectomies
were purchased from ProteoGenex (Culver City, CA). The
needle biopsy tumors were microdissected to exclude
normal-appearing tissue. The selected radical prostatec-
tomy blocks spanned a wide range of gene expression and
range of GPS. Gleason score was assigned using the 2005
International Society of Urological Pathology Consensus
guidelines [20].
RNA extraction
Paraffin from FPE samples was solubilized by Shandon
Xylene Substitute (Thermo Fisher Scientific, Waltham,
MA) and removed. Tissue was lysed and protein was
digested with Proteinase K (800μg; Beckman Coulter,
Beverly, MA). Nucleic acids were bound to paramagnetic
beads using the Agencourt® FormaPure Kit (Beckman
Coulter, Beverly, MA) and manipulated using Tecan® li-
quid handling robots (Tecan, Männedorf, Switzerland)
with an integrated KingFisher® Flex magnetic particle
processor (Thermo Fisher Scientific, Waltham, MA).
DNA was digested with 200 units of DNaseI (Promega,
Madison, WI). Purified RNA was released from the
paramagnetic beads and suspended in water.
RNA quantitation
RNA was quantified using the RiboGreen® fluorescence
method (Invitrogen, Carlsbad, CA) according to the
manufacturer’s instructions. The limit of quantitation for
the assay was 0.5 ng/μL.
Reverse transcription
RNA (up to 20 ng) was converted to complementary
DNA (cDNA) by combining the Omniscript® RT kit
(Qiagen, Valencia, CA) and a specific reverse primer for
each gene assay using Tecan liquid handling robots. All
primers (final concentration 50 nmol/L) were purchased
from Integrated DNA Technologies (Coralville, IA). TheRT reaction (30 μL) was incubated at 37°C for 60
minutes and then inactivated at 93°C for 5 minutes.Preamplification
The cDNA was preamplified using custom TaqMan® Pre-
Amp Master Mix (Life Technologies, Carlsbad, CA) and
custom forward and reverse primers (55 nM final concen-
tration) for each target gene, including the control assay
for genomic DNA (gDNA) detection. The reactions were
assembled using Tecan liquid handling robots, placed in a
thermocycler (BioRad, Hercules, CA) and incubated under
the following conditions: 95°C for 10 min followed by 8
cycles of 95°C for 15 sec and 60°C for 4 min.qPCR and genomic DNA detection
The amplified product was mixed with the forward and
reverse primers and probes (Black Hole Quencher-2,
Integrated DNA Technologies) for each of the gene as-
says and for the gDNA detection assay (ARF1_promoter,
designed to amplify a promoter region of ARF1) using
Tecan liquid handling robots. QuantiTect® Primer Assay
master mix (Qiagen, Valencia, CA) was used, and the
5 μL reaction was amplified for 45 cycles in a LightCycler®
480 (Roche Applied Science, Indianapolis, IN) under the
following conditions: enzyme activation (95°C, 15 min),
amplification (95°C for 20 sec and 60°C for 45 sec; 45 cy-
cles in total), cooling (40°C, 5 sec). The level of expression
was calculated with the crossing point (Cp) method
implemented by the Roche LightCycler 480 software ver-
sion 1.5. All gene assays were measured in triplicate and
required at least 2 valid wells. Oligonucleotide and
amplicon sequences can be found in the Additional file 1
and Additional file 2, respectively.Reference gene normalization and Genomic Prostate
Score calculation
The five reference genes (ARF1, ATP5E, CLTC, GPS1
and PGK1) were selected in an independent study for
their low inter-patient variability, lack of relationship to
clinical outcome and robust analytical performance (data
not shown). Reference gene normalization was used to
adjust for potential sources of pre-analytical variability,
such as fixation, RNA fragmentation and tissue quality,
analytical variation including assay plate (RT, qPCR) and
instrumentation (liquid handler or LC480), and varying
RNA inputs (with 20 ng as the target input). Gene ex-
pression was normalized by subtracting the aggregated
expression of the reference genes from the weighted
mean Cp for each of the 12 informative genes and cen-
tering by adding 10 units to the result. The formula used
to calculate the GPS is shown in Figure 1.
COL1A1
Figure 1 Calculation of Genomic Prostate Score (GPS). The aggregate expression of 5 reference genes was used to reference normalize the
expression of the 12 cancer-related genes. Normalized gene expression was used to calculate the individual group scores: stromal group score,
cellular organization score, androgen groups score and proliferation score. Each of those group scores is algorithmically combined to calculate
the unscaled Genomic Prostate Score (GPSu); the GPSu is then scaled to a 100-unit range GPS. A negative coefficient in the calculation of the
GPS is associated with better outcome whereas a positive coefficient is associated with poorer outcome.
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Linearity was assessed by serially diluting RNA and analyz-
ing gene expression as a function of 14 input concentra-
tions of RNA extracted from FPE prostate tumor tissue.
Two different starting RNA concentrations were used
(1,638 ng/well and 204 ng/well) where the higher starting
concentration was used for the genes with the lowest ex-
pression levels (TPX2 and SRD5A2), and the lower starting
concentration was used for all other genes. For each
starting concentration, three independent series of two-fold
serial dilutions were prepared using a Tecan liquid handling
robot. The serially diluted RNA was converted to cDNA,
preamplified for 8 cycles of PCR and taken through 45 cy-
cles of qPCR. The linearity of signal response between the
measured gene expression (Cp) and the log base 2 of RNA
concentration was evaluated for each of the individual gene
assays. In total, for each gene and RNA concentration, 9-
replicate PCR measurements were recorded and analyzed.Linearity was assessed for each gene using the polyno-
mial method developed by Krouwer et al. [21]. The poly-
nomial method utilized in these analyses first fit a
quadratic and cubic regression models and compares,
through tests of significance on the quadratic and/or
cubic terms, whether the extra linear models are better
fits to the data than a linear regression. Heteroscedas-
ticity of the error variance was modeled as a log-linear
function of (known) log input concentration. These tests
were used to determine the presence of significant non-
linearity (at a 0.05 alpha level). If significant non-
linearity was detected, then the predicted Cp value from
the best fitting polynomial model was compared with
the corresponding predicted Cp value from the linear
model. This difference in predicted Cp values (deviation
from linearity, (DL)) was calculated at each input
concentration. A maximum DL across concentrations
of < 1 Cp was used to determine that a gene is
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given concentration, if the DL was greater than or equal
to 1 Cp, then that concentration was removed from the
linear range until all concentrations met the DL criteria,
thereby defining the limit of quantitation (LOQ).
Additionally, to control large residual variation at low
concentrations, which is a consequence of pream-
plification of small starting amounts of cDNA, an
additional criterion was applied where concentrations
below and including the point at which the residual
standard deviation was > 1.5 Cp were removed from
the linear range, and polynomial model assessments
were repeated.
Amplification efficiency
Estimates of amplification efficiencies were obtained for
all gene assays and are provided by the formula:
Efficiency ¼ 100 2−1=slope−1
 
where the slope is estimated from the regression of Cp
measurements versus (known) log base 2 RNA concen-
tration described above.
Analytical accuracy
The analytical accuracy of predicted RNA concentrations
relative to the (known) input RNA concentrations was
estimated for each of the 17 genes separately. Specific-
ally, for every evaluable Cp measurement, an inverse
prediction of RNA concentration was derived from the
final linear model:
y ¼ b^0 þ b^1 log2 xð Þ
An estimate of the accuracy of the assay was given by
the mean percent bias in prediction at each known RNA








where Xk is the (known) input RNA concentration for the
kth level and x^ijk was the predicted RNA concentration
obtained from inverse prediction for the ith plate
(i=1,2,3), jth well (j=1,2,3) and kth RNA concentration
level, mi was the number of valid wells on the i
th plate,
and m was the total number of valid wells across all
plates. Analyses were performed using restricted max-
imum likelihood estimation (REML) in the PROC
MIXED procedure of SAS version 9.2.Analytical sensitivity
The analytical sensitivity of each of the gene assays
was evaluated separately. Specifically, for each gene a
nonlinear mixed effects model with log-linear variance
function or unstructured covariance was used to model
the expected heteroscedasticity in intra-assay response as
a function of RNA concentration. This information was
used to estimate the Limit of Detection (LOD) and LOQ
of the assay on the Cp scale. For each of the 17 gene
assays, the LOD was estimated by a lower 95% confidence
bound on the mean expression at zero concentration (nat-
ural original scale). Similarly, the LOQ on the Cp scale
was estimated by the upper one-sided 95% confidence
interval of the fitted (linear) model at the inverse predic-
tion of ymin or at the minimum concentration fulfilling the
linear range criteria if the inverse prediction of ymin was
less than the lower linear range limit (on the concentra-
tion scale). Analyses were performed using an iterative
estimation scheme involving the PROC MIXED and the
PROC NLMIXED procedure in SAS version 9.2.
Analytical precision and reproducibility
Data for the precision and reproducibility were gener-
ated from 10 different FPE prostate cancer samples that
were run 9 times each: 3 replicates at each of 3 different
RNA inputs (5 ng, 10 ng, and 20 ng). Both precision and
reproducibility were generated using multiple lots of RT-
PCR reagents, multiple PCR instruments and multiple
Tecan liquid-handling robots. The precision component
for each of the 12 informative genes as well as the GPS
was defined as the within RNA input standard deviation
captured in the residual variation term from the linear
mixed model described below:
Yijk ¼ μþ αi þ λjþεijk
Where Yijk was the outcome measurement (either GPS
or reference normalized gene expression), μ was the
overall mean effect, αi was the random effect of the i
th
sample (i=1,2,..,10), distributed N(0,σα
2), λj was the fixed
effect of the jth RNA Input (j=1,2,3), εijk was the residual
error ~ N(0, σε
2) where k indexes replicate (k=1,2,3),
assumed independent of αi.
The reproducibility component for each of the 12
informative genes as well as the GPS was defined as
the within and between RNA input standard deviation,
captured in the residual variation term from the linear
mixed model described below:
Yijk ¼ μþ αiþεijk
Where Yijk was the outcome measurement (either GPS
or reference normalized gene expression), μ was the
overall mean effect, αi was the random effect of the i
th
sample (i=1,2,..,10), distributed N(0,σα
2), εijk was the
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2) where k indexes replicate
(k=1,2,3), assumed independent of αi.
Assay controls
Each Oncotype DX Prostate Cancer Assay RT and
preamplification assay plate has 5 wells containing pro-
cessing controls: RNA extracted from prostate
cancer FPE (a positive control for reverse transcription,
preamplification and qPCR), human genomic DNA
(a positive control for gDNA detection, Promega, Madison,
WI), and 3 wells containing nuclease-free water (a negative
control for contamination). In addition, all qPCR plates
have 12 wells of positive (gDNA) and 12 wells of negative
(nuclease-free water) controls.
Results
Distribution of RNA yields in the smallest diagnostic
prostate biopsies
We estimated that the smallest diagnostic biopsies would
contain 0.0225 mm3 of tumor volume (1 mm tumor a
Quantiles
100.0% maximum 165.0 ng
75.0% quartile 63.5 ng
50.0% median 50.8 ng
25.0% quartile 34.1 ng
10% 21.7 ng
2.5% 15.7 ng
0.0% minimum 15.7 ng
Moments
Mean 53.1 ng
Standard Deviation 28.1 ng
Standard Err Mean 4.1 ng
Upper 95% Mean 61.4 ng
Lower 95% Mean 44.7 ng
N 46
Figure 2 Estimates of RNA yields in the smallest diagnostic biopsies.
collected between 2003 and 2008 by the Cleveland Clinic was extracted an
volumes were measured and all results were adjusted to represent RNA yie
0.75 mm width of diagnostic biopsies x 0.030 mm tumor depth). (b) AUA l
Cleveland Clinic between 1999 and 2007 with available biopsy tissues were
extracted and RNA yields were measured using the RiboGreen method. Tu
RNA yields in the target tumor volume of 0.0225 mm3 (1 mm tumor lengthlength × 0.75 mm biopsy core width × 0.030 mm tumor
depth (based on availability of six 5 μm sections)) and
sought to investigate distribution of RNA yields in such
samples. In two separate studies [22,23], RNA was
extracted from 46 and 167 biopsies. Using this data, the
average RNA yields in the targeted tumor volume were
estimated to be less than 50 ng and the lowest quartile
was estimated to contain between 19 and 34 ng of RNA
(Figure 2a and 2b). Considering variability in clinical
practice, it is expected that biopsies from men with pros-
tate cancer will be encountered which contain less than
this amount of RNA; as such, we targeted an RNA input
for the assay below the lower limit of the lowest quartile,
in order to meet the needs of all patients.
Amplification efficiency
In order for normalization and multianalyte GPS result
calculation to be accurate, amplification efficiencies of
individual gene assays were required to be similar [24],
defined as the median ± 20%. The median amplificationb
Quantiles
100.0% maximum 129.6 ng
75.0% quartile 38.6 ng 
50.0% median 28.9 ng
25.0% quartile 19.3 ng
10% 13.6 ng
2.5% 4.6 ng
0.0% minimum 2.8 ng
Moments
Mean 32.2 ng
Standard Deviation 19.0 ng
Standard Err Mean 1.47 ng
Upper 95% Mean 35.1 ng
Lower 95% Mean 29.3 ng
N 167
(a) RNA from 46 formalin-fixed prostate needle core biopsy specimens
d RNA yields were measured using the RiboGreen method. Tumor
lds in the target tumor volume of 0.0225 mm3 (1 mm tumor length x
ow and intermediate risk patients treated with radical prostatectomy at
included in the study. In total, RNA from 167 diagnostic biopsies was
mor volumes were measured and all results were adjusted to represent
x 0.75 mm width of diagnostic biopsies x 0.030 mm tumor depth).
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ciencies were within ± 6.3% of that value, demonstrating
that gene-specific assay performance was comparable for
all assays. Amplification efficiencies ranged from 88%
(AZGP1) to 100% (TPM2). Amplification efficiencies of
individual assays, including 95% confidence intervals are
shown in Table 1.
Analytical sensitivity
For a multianalyte assay to be clinically useful, it must also
be able to distinguish between signal and background non-
specific signal. All gene assays had LODs that surpassed
the pre-specified Cp criteria of 35. Moreover, to make ac-
curate expression measurements, LOQs need to be in a
range of Cp values that are higher than the estimates for
gene expression within the intended specimen type. Ac-
ceptance criteria were pre-specified for each gene assay
separately, and all were met. Most of the assays had esti-
mated LOQs between Cp=33 and Cp=35 effectively indi-
cating that most individual assays can accurately quantitate
several copies of RNA. The lowest estimated LOQ of 29.4
was for the KLK2 assay. Considering that this value was
established at its final dilution point, it is possible that the
true LOQ is higher. However, even with this estimated
LOQ, the discriminative capability of the KLK2 assay is ap-
propriate for the expected population distribution (medianTable 1 Amplification efficiencies of individual gene
assays in the Oncotype DX Prostate Cancer Assay
reporting the GPS






ARF1 93.9 92.8 95.0
ATP5E 90.2 88.2 92.2
AZGP1 88.1 86.5 89.7
BGN 92.5 90.5 94.7
CLTC 97.2 95.9 98.6
COL1A1 95.4 94.5 96.3
FAM13C1 88.5 85.8 91.3
FLNC 96.9 94.9 99.0
GPS1 94.4 92.4 96.6
GSN 91.5 89.7 93.4
GSTM2 95.9 93.8 98.2
KLK2 92.4 91.7 93.1
PGK1 89.9 88.4 91.4
SFRP4 93.9 91.2 96.7
SRD5A2 98.7 96.3 101.4
TPM2 100.2 98.8 101.8
TPX2 98.9 97.1 100.7
Estimated amplification efficiencies and 95% confidence intervals for the 17
genes comprising the GPS derived from a 15-point dilution series.population expression level has been estimated to be ap-
proximately Cp=20). Table 2 shows data for the estimated
LOQ and LOD for each gene assay.
Linear range
FPE RNA was serially diluted two-fold and performance
of the individual gene assays was assessed over a linear
range of 14 RNA concentrations. Table 3 lists the linear
ranges for all gene assays, which ranged from 10 log
units (FLNC, GSTM2) to the full 14 log units (16,384-
fold) RNA concentrations studied (ARF1, BGN, CLTC,
COL1A1, KLK2, TPM2). The smallest amounts that
could be accurately quantified ranged from 0.025 ng to
1.6 ng RNA per PCR well. These results demonstrate
the performance of these gene assays to quantify cDNA
over a wide range of input concentrations that can be
encountered in small prostate needle biopsies.
Analytical accuracy
For all 17 GPS gene-specific assays, the absolute value of
the average percent accuracy at the nominal, one-half
and the one-quarter qPCR input was required to be less
than 25% in order to meet pre-specified criteria. All as-
says met these criteria and the results for accuracy are
listed in Table 4. The largest analytical bias was observed
for the ATP5E assay (9.7%) and all other assays displayed
a bias smaller than 5% in absolute value. Both the ampli-
fication efficiency and the accuracy at the individualTable 2 Limits of quantitation and detection


















Analytical sensitivity (estimated Limits of Quantitation and Limits of Detection)
for each of the 17 genes comprising the GPS derived from the 15-point
dilution series.












ARF1 2-5.3 to 27.7 <.0001 0.1191 0.37
ATP5E 2-3.3 to 27.7 <.0001 0.0418 0.82
AZGP1 2-3.3 to 27.7 0.0006 0.1143 0.46
BGN 2-5.3 to 27.7 0.0030 0.4064 0.57
CLTC 2-5.3 to 27.7 0.0145 0.2198 0.28
COL1A1 2-5.3 to 27.7 0.2406 0.0268 0.31
FAM13C1 2-3.3 to 27.7 0.9180 0.0026 0.81
FLNC 2-1.3 to 27.7 0.0002 0.0001 0.17
GPS1 2-3.3 to 27.7 0.3704 <.0001 0.40
GSN 2-2.3 to 27.7 <.0001 0.8081 0.57
GSTM2 2-1.3 to 27.7 0.2461 0.0009 0.23
KLK2 2-5.3 to 27.7 0.3600 0.0008 0.16
PGK1 2-3.3 to 27.7 0.0224 0.5250 0.30
SFRP4 2-2.3 to 27.7 0.5033 0.1019 N/A
SRD5A2 20.7 to 210.7 0.0002 0.1016 0.34
TPM2 2-5.3 to 27.7 <.0001 0.2190 0.43
TPX2 20.7 to 210.7 0.5396 0.5799 N/A
N/A: No statistically significant departure from linearity.
Estimated linear ranges, associated p-values for quadratic or cubic regression
models and maximum deviations from linearity for each of the 17 genes.
The results were calculated using the data obtained from the 15-point
dilution series.
Table 4 Analytical accuracy


















The estimated analytical accuracy of predicted RNA concentrations relative to
the known input RNA concentrations for each of the 17 Oncotype DX Prostate
Cancer Assay gene assays; the average % bias is taken over the nominal,
½ and ¼ qPCR input levels.
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tect the doubling in the amount of RNA for individual
genes in 1 Cp increments. The combination of low mea-
sures of biases and amplification efficiencies approaching
100% demonstrated robust analytical performance at
RNA inputs expected to be found in prostate biopsies.
Precision and reproducibility
Precision was evaluated by examining variation within the
same RNA input, and reproducibility incorporated both
within and between RNA input variation. Pre-specified ac-
ceptance criteria were set for the average within RNA input
standard deviation pooled between 20 ng, 10 ng and 5 ng
RNA input (precision) and the within and between RNA
input (20 ng, 10 ng and 5 ng) standard deviation (reprodu-
cibility). The lowest input of 5 ng was chosen to mirror the
lowest 2.5 percentile of the 0.0225 mm3 tumors. A total of
10 blocks were chosen to span a wide range of GPS results.
Each RNA extract was processed three separate times at
three different input levels (5 ng, 10 ng and 20 ng) by sev-
eral operators over a two week period. Multiple lots of oli-
gonucleotides, preamplification master mixes, and qPCR
master mixes were used and processed on different Tecan
liquid-handling robots and LightCycler 480 instruments.
The standard deviation for precision was 0.21 Cp orsmaller for individual gene assays. For GPS, standard devi-
ation was 1.86 units on the 100-unit scale. The standard
deviation for reproducibility was also 0.21 Cp or smaller
for all assays. Reproducibility variation for the GPS was
2.11 units on the 100-unit scale. Tables 5 and 6 show re-
sults for the gene assays and the GPS for precision and re-
producibility, respectively. All precision and reproducibility
measurements met pre-specified acceptance criteria thus
demonstrating a robust analytical performance. These re-
sults establish that average of the reference genes can be
used to enable processing of variable RNA inputs while
maintaining high precision and reproducibility.
Controls
The box plots presented in Figure 3 illustrate the per-
formance of the RT-PCR positive control across 18 con-
trol plates (54 individual Cp measurements per gene)
run during analytical validation and the subsequent clin-
ical validation. Table 7 lists the summary statistics, in-
cluding standard deviations which were calculated on
the non-normalized scale. These plates were run on
multiple PCR and liquid handling robots by multiple op-
erators, using multiple lots of critical reagents spanning
a period of 20 weeks. The performance illustrates a
process that is well in control with overall very low vari-
ation (the largest SD was 0.33 Cp). Figure 4 presents box
plots of the gDNA and qPCR positive control, which are










ARF1 0.08 0.07 0.10
ATP5E 0.15 0.13 0.18
AZGP1 0.14 0.12 0.16
BGN 0.11 0.09 0.13
CLTC 0.07 0.06 0.09
COL1A1 0.10 0.08 0.11
FAM13C1 0.10 0.09 0.12
FLNC 0.11 0.09 0.13
GPS1 0.08 0.07 0.09
GSN 0.10 0.09 0.12
GSTM2 0.13 0.11 0.15
KLK2 0.08 0.07 0.09
PGK1 0.08 0.07 0.10
SFRP4 0.11 0.10 0.13
SRD5A2 0.20 0.17 0.23
TPM2 0.10 0.09 0.12
TPX2 0.21 0.18 0.25
GPS 1.86 1.60 2.20
Analytical precision (assay variation within a given RNA input level ) of the 17
Oncotype DX prostate gene assays and GPS was derived from 10 different FPE
prostate cancer samples that were run 9 times each: 3 replicates at each of 3
different RNA inputs: 5 ng, 10 ng and 20 ng (target). The within RNA input
level sources of variation include instruments (qPCR and Tecan liquid handling
robots), reagents lots (oligonucleotides, preamplification master mix and qPCR
master mix), operator and time (processing spanned 2 calendar weeks).










ARF1 0.09 0.08 0.11
ATP5E 0.17 0.15 0.20
AZGP1 0.15 0.13 0.18
BGN 0.11 0.09 0.13
CLTC 0.07 0.06 0.09
COL1A1 0.10 0.09 0.12
FAM13C1 0.11 0.09 0.12
FLNC 0.11 0.10 0.13
GPS1 0.08 0.07 0.09
GSN 0.14 0.12 0.16
GSTM2 0.14 0.12 0.16
KLK2 0.08 0.07 0.09
PGK1 0.10 0.09 0.12
SFRP4 0.12 0.10 0.14
SRD5A2 0.20 0.17 0.23
TPM2 0.10 0.09 0.12
TPX2 0.21 0.18 0.25
GPS 2.11 1.83 2.50
Analytical reproducibility (assay variation incorporating both between RNA
input level and within RNA input level variation) of the 17 Oncotype DX
prostate gene assays and GPS was derived from 10 different FPE prostate
cancer samples that were run 9 times each: 3 replicates at each of 3 different
RNA inputs: 5 ng, 10 ng and 20 ng (target). The within RNA input level sources
of variation include instruments (qPCR and Tecan liquid handling robots),
reagents lots (oligonucleotides, preamplification master mix and qPCR master
mix), operator and time (processing spanned 2 calendar weeks).
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http://www.biomedcentral.com/1471-2164/14/690also reflective of good assay performance due to their
low variability.Discussion
Prostate cancer is one of the most common malignan-
cies in adult males and is typically diagnosed using small
needle core biopsies. While many men with newly diag-
nosed prostate cancer harbor indolent disease, most are
treated with immediate surgery or radiation. A molecu-
lar assay capable of obtaining reliable, clinically relevant
genomic information from small amounts of tumor tis-
sue available in diagnostic core biopsies could help more
accurately identify men with low risk of clinical progres-
sion who could be managed by active surveillance. In
this manuscript we demonstrate that the Oncotype DX
Prostate Cancer Assay can accurately and reproducibly
quantitate gene expression at RNA input levels 110–180
fold less [6,7] than the other Oncotype DX assays.
The Oncotype DX Prostate Cancer Assay is a multi-
gene RT-PCR assay specifically designed to analyze under-
lying tumor biology in tumor tissue from diagnostic FPEcore needle biopsies. In order for a biomarker to enter
wide clinical practice, evidence of strong analytical validity
needs to be demonstrated [5]. Prior analytical validation
studies performed by Genomic Health, Inc. have recently
been cited as a model of how such validation studies
should be performed [25] and a similar approach to ana-
lytical validation was used for the Oncotype DX Prostate
Cancer Assay. All pre-specified analytical criteria (i.e.
amplification efficiency, analytical sensitivity, bias, repro-
ducibility and precision) were met, and the analytical assay
has been demonstrated to be reliable for clinical use even
for patients from whom only limiting amounts of biopsy
material are available.
Prostate cancer is often diagnosed from a single positive
diagnostic biopsy containing no more than 1 mm of tumor
in the greatest dimension. Data suggested that the lowest
quartile of such biopsies with 30 microns of available tissue
would contain between 19 and 34 ng of RNA. In order to
enable accurate and reproducible quantitation of gene ex-
pression when limiting copies of target RNA are present, a
number of analytical changes to the Oncotype DX platform
Figure 3 Boxplots for the RT-PCR positive control during analytical and clinical validation studies. Boxplots summarizing performance of
each gene over analytical and clinical validation for RT-PCR positive control (prostate cancer FPE pool) representing 18 RT-PCR control plates
stratified by gene (ARF1, ATP5E, CLTC, GPS1 and PGK1 are reference genes). Each RT-PCR control plate contains one positive control and each
gene is measured in triplicate. Standard deviations ranged from 0.19 Cp to 0.33 Cp. The box represents the inter-quartile range, the line in the
box represents the median and the diamond is centered at the mean. The whiskers represent minimum and maximum values observed.
Table 7 Performance of the RT-PCR positive control
Gene Assay Mean Median SD
ARF1 22.7 22.7 0.20
ATP5E 24.3 24.2 0.33
AZGP1 24.6 24.6 0.23
BGN 23.7 23.7 0.22
CLTC 24.0 24.0 0.19
COL1A1 22.4 22.5 0.25
FAM13C1 25.8 25.8 0.23
FLNC 25.3 25.3 0.24
GPS1 25.3 25.3 0.20
GSN 25.9 25.9 0.29
GSTM2 26.7 26.7 0.21
KLK2 19.4 19.4 0.20
PGK1 26.3 26.3 0.22
SFRP4 26.7 26.7 0.23
SRD5A2 28.1 28.0 0.32
TPM2 22.6 22.6 0.21
TPX2 29.6 29.6 0.25
Summary statistics, including standard deviations for the RT-PCR positive
control performance during analytical and clinical validation were calculated
on the non-normalized scale. The plates were assembled using multiple PCR
and liquid handling robots and by multiple operators, using multiple lots of
critical reagents spanning a period of 20 weeks (N=54 individual
Cp measurements).
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http://www.biomedcentral.com/1471-2164/14/690used for Breast and Colon cancer were required. More spe-
cifically, the multiplexed preamplification step was intro-
duced to create multiple copies of the starting RNA prior
to quantitative assessment of gene expression. Given the
very low yields and the resulting limitations to accurate
measurement of extracted RNA for many samples, accept-
ance criteria for the assay include a specification of the
average of the reference genes rather than on mass of RNA
input as the primary specification for sample quality. This,
in turn, allows for the processing of variable RNA inputs,
and samples containing as little as 5 ng of RNA have gen-
erated reproducible results as demonstrated by the repro-
ducibility of the individual genes and the GPS (Table 6).
Volumes of the reverse transcription and qPCR reactions
were reduced to preserve the genetic material, and robotic
liquid handling was optimized for smaller volumes. A new
genomic DNA detection assay targeting the promoter re-
gion of one of the reference genes was created, and gDNA
assessment performed as part of the final qPCR step. Mul-
tiple positive and negative assay controls are included in
every assay run to ensure consistent performing of the
analytical process.
The estimates of analytical precision and reproducibil-
ity were obtained by analyzing 10 prostate tumor RNA
samples on multiple instruments, using multiple reagent
lots, by various operators over a period of 2 weeks.
Standard deviation for precision for the analytical
process was at or below 0.21 Cp for all gene assays and
1.86 GPS units on a 100 unit scale. Reproducibility of
Figure 4 Boxplots of genomic DNA detection and qPCR positive controls. Boxplots summarizing the performance of genomic DNA
detection and qPCR positive controls over Analytical and Clinical Validation. The box represents the inter-quartile range, the line in the box
represents the median and the diamond is centered at the mean. The whiskers represent minimum and maximum values observed.
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tioned sources of analytical variability, incorporated vari-
ation in RNA input levels (i.e. 5 ng, 10 ng and 20 ng
inputs). Reproducibility standard deviation for the ana-
lytical process of the individual gene assays was at or
below 0.21 Cp, and for the overall score was 2.11 GPS
units. Given that the estimated total standard deviation
in the GPS (including all pre-analytical, tissue related
and biological between patient variability) is approxi-
mately 11.4, the analytical assay variability is estimated
to account for only 3.4% (= 100 × 2.112 / 11.42) of the
total variation. In a separate study (E. Klein, manuscript
submitted), within-block reproducibility of the GPS was
assessed in biopsies from 46 patients (up to 4 separate
samples per biopsy-containing block). The within block
standard deviation for GPS in that study was 2.8 GPS
units (95% CI, 2.5 to 3.1) indicating excellent reproduci-
bility even when histological variability is introduced.
Average amplification efficiency of the 17 gene assays in
the Oncotype DX Prostate Cancer Assay was 93%, and all
gene assays were within ±6% of that value. High analytical
sensitivity, wide linear range (at least 10 logs) and low bias
(under 9.7%) demonstrate that the assay is able to measure
accurately gene expression on a wide population range
using a very limited amount of RNA.
The Oncotype DX Prostate Cancer Assay has been
clinically validated [19], demonstrating that the GPS,
assessed in diagnostic biopsy tissue, can predict the like-
lihood of the presence of adverse pathology (high-grade
and/or high-stage disease), and that it complements
existing pre-treatment risk assessment tools such as PSAlevels, Gleason Score, and clinical stage. The assay is
intended to help guide treatment decisions in early-stage
prostate cancer, including the decision between immedi-
ate therapy and active surveillance. As evidence that the
analytical assay was designed well for its intended use to
test RNA from small biopsies, in a clinical validation
study, valid GPS results were generated for more than
95% of samples requiring 1 mm and 30 microns of
tumor tissue [19].
Conclusion
Optimization of the Oncotype DX platform has enabled
the development and analytical validation of the
Oncotype DX Prostate Cancer Assay for use with pros-
tate biopsy specimens. This RT-PCR assay has been clin-
ically validated to predict the risk of high grade and/or
non-organ confined disease at radical prostatectomy
using biopsy samples containing as little as 1 mm of
tumor tissue. The Oncotype DX Prostate Cancer Assay
complements traditional clinical and pathologic diagnos-
tic features and will assist clinicians to discriminate pa-
tients with indolent prostate cancer from aggressive
prostate cancer to help make the most appropriate treat-
ment decisions.
Additional files
Additional file 1: Oligonucleotide Sequences for each primer and
probe.
Additional file 2: Amplicon Sequences for 17 genes in the
Oncotype DX GPS.
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